International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL.

ABSTRACT: Bruton's tyrosine kinase inhibitors (BTKis) have altered the treatment landscape for chronic lymphocytic leukemia (CLL) by offering effective and well-tolerated therapeutic options. However, since the approval of ibrutinib, concern has risen regarding the risk of cardiovascular (CV) adverse events, including atrial fibrillation (AF), hypertension, and heart failure. Newer BTKis appear to have lower CV risks, but data are limited. It is important to understand the risks posed by BTKis and how those risks interact with individual patients, and we convened a panel of physicians with expertise in CLL and CV toxicities in oncology to develop evidence-based consensus recommendations for community hematologists and oncologists. Care providers should thoroughly assess a patient's CV risk level bef

SUBMITTER: Awan FT 

PROVIDER: S-EPMC9631706 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature